An international panel of the foremost researchers on infectious disease and antimicrobials has formed new guidelines on the use of polymyxins, a class of antibiotics employed as a last resort to treat deadly, drug-resistant bacteria.

Pseudomonas aeruginosa/CDC
Pseudomonas aeruginosa/CDC

The guidelines, published last month in Pharmacotherapy, set new standards for the clinical use of polymyxins, including on maximum dosage, treatment strategies and best practice for use in combination with other antibiotics.

“There is considerable confusion on how to optimally use the polymyxin antibiotics. These guidelines represent consensus recommendations from expert clinicians and scientists around the globe…”, said
Brian Tsuji, professor of pharmacy practice in the University at Buffalo School of Pharmacy and Pharmaceutical Sciences